{"id":"W4410338114","doi":"10.1016/j.euo.2025.02.015","title":"Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"Bayer; Astellas Pharma US","keywords":"Medicine; Docetaxel; Pembrolizumab; Prostate cancer; Prednisone; Oncology; Internal medicine; Abiraterone; Enzalutamide; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005160211,0.000537068,0.001038727,0.0003388911,0.0001910079,0.0008140667,0.0004729234,0.0005008085,0.001935851],"category_scores_gemma":[0.003512548,0.0002514432,0.002273726,0.0006819431,0.0002872019,0.0007033086,0.0006197852,0.001149244,0.0001864582],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005847011,"about_ca_system_score_gemma":0.0005877175,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004460889,"about_ca_topic_score_gemma":0.0008759287,"domain_scores_codex":[0.9974294,0.00167574,0.0001538158,0.0002892991,0.0003002835,0.0001514134],"domain_scores_gemma":[0.997488,0.0007604196,0.001283396,0.0001082713,0.0001145185,0.000245413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5895169,0.005461123,0.2211613,0.002922601,0.01249332,0.0002601025,0.0002562716,0.005389778,0.005684677,0.000341518,0.002713318,0.1537991],"study_design_scores_gemma":[0.08445146,0.1433975,0.7442968,0.0004427619,0.01051288,0.0008328953,0.0002085092,0.007132925,0.002767197,0.0006136187,0.005242056,0.0001013057],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990798,0.006778346,0.0003433927,0.0002821228,0.00003400172,0.0001825271,0.0008190844,0.00001166059,0.0007508486],"genre_scores_gemma":[0.9975514,0.0007332414,0.000308623,0.0001287466,0.00004634326,0.0001713152,0.0009057968,0.000002229525,0.0001523404],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005160211,"threshold_uncertainty_score":0.02729017,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01753613448020711,"score_gpt":0.3190061985177405,"score_spread":0.3014700640375334,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}